CD4 and ovarian cancer: It can also upregulate activation markers and cytokine production of CD4+ and CD8+ T cells from healthy donors, as well as promote ADCC in an NK cell-mediated in vitro assay and deplete Tregs in ovarian cancer ascites samples; all these results are going to be retested in patient-derived xenograft (PDX) mouse models (65, 66).